Update SRA to SRIA 28 March 2017 Linda van Gaalen
Update SRA First SRA approved 2013 New CSA (EXEDRA): Add Innovation to SRA => SRIA Other WPs CSA will provide input Alignment necessary: with other SR(I)A s (eg. SRIA-IMI) stakeholders / industry national action plans WHO Global Action Plan
Important choices! SRIA specific for JPIAMR or - General SRIA (added value JPI indicated) Update or amendment?
Procedure 1. Desk study existing SRIA s 2. Questionnaires: critical areas to reappraise (MB & SAB). 3. Workshops to prioritise research areas: roadmaps by SRIA pillar (WP 2 & EXEDRA WS) 4. Engagement with industry and stakeholders (WP3 & WP 4) 5. Draft 1 SRIA with SAB 6. Feedback: MB, Stakeholders & Industry 7. Draft 2 SRIA with SAB 8. Approval MB
What do we need MB approval on procedure Editorial board (?) Scope and strategic plan (CSA) List of stakeholders and industry to contact List of critical areas to reappraise from questionnaires List of prioritisation research areas from roadmaps Input from expert meeting Approval MB on SRIA Broad attention for SRIA through communication network
Planning and relation to EXEDRA activities M1-12 Relation What WP Task leader - organiser Base of the update SRIA is scope and strategic plan Opinion of SAB and MB Alignment with other SRA's (WHO and others) Editorial board for Update SRA Engagement stakeholders / other countries for Update SRA Engagement stakeholders / other countries for Update SRA Scope - strategic plan JPIAMR EXEDRA Questionnaire to MB - SAB on current SRA Due date (Month) 2 ISCII - Spain 3 5.1 ZON - Netherlands 5 SAB meeting ZON - Netherlands 6 Desk study & consultation partner 5.1 ZON - Netherlands 7 countries Work Shop Environmental SRC - Sweden 9 Work Shop Virtual Institute DLR - Germany 9 Work Shop Interventions ISCII - Spain 10 MB Meeting SRC - Sweden 10 CSA EXEDRA meeting SRC - Sweden 10 SAB meeting ZON - Netherlands 12 Establish editorial board 5.1 ZON - Netherlands 12 SAB - MB - SH? Mapping and analysis international collaboration 3 DLR - Germany 12 Strengthen dialogue with industry 4.2 ANR - France 12
Planning and relation to EXEDRA activities M13-24 Relation What WP Task leader - organiser Engagement stakeholders / other countries alignment strategy with national policy makers and international SH Draft 1 SAB development Draft 1 jan-march 2018 Due date (month) 4.1 SRC - Sweden 15 5.1 ZON - Netherlands 16 Stakeholder and industry feedback Expert meeting on Draft 1 April-May 2018 Draft 2 SAB development Draft 2 May - June 2018 5.1 ZON - Netherlands 17 5.1 ZON - Netherlands 18 Feedback Participants on draft 2 SRIA Distribute draft 2 SRIA 5.1 ZON - Netherlands 18 Final SRIA SAB development Final SRIA Sept -Oct 2018 5.1 ZON - Netherlands 19 Final approval of Distribute final SRIA 5.1 ZON - Netherlands 23 member countries SRIA October 2018 Update SRIA publication of the SRIA 5.1 ZON - Netherlands 24 Use communication channels Promotion SRIA 6.2 SRC - Sweden 12-48
Questions to take into account 1. Which innovation aspects will be an addition to the present SRA? 2. How does the SRA relate and align with industry and initiatives such as IMI, etc? 3. How can translational research be stimulated? 4. How can key networks of academic and industrial excellence be developed and involved? 5. What are priorities in the current pillars? 6. What are key areas for implementation of the SRA? 7. How can we measure or define value added to the SRIA? 8. What are other key areas or instruments we should think of?
Current strategic research priorities SRA A. Therapeutics B. Diagnostics C. Surveillance D. Transmission E. Environment F. Interventions
Objectives WHO Global Action Plan AMR 1. Improve awareness and understanding of antimicrobial resistance through effective communication, education and training 2. Strengthen the knowledge and evidence base through surveillance and research 3. Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures 4. Optimize the use of antimicrobial medicines in human and animal health 5. Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions
Questions 1. General or specific SRIA? 2. Update or amendment? 3. Approval procedure 4. Editorial board (M12)? Yes / No? If yes; any suggestions? MB, SAB, Stakeholders, Others @: abr@zonmw.nl